The FDA has granted Fast Track Designation to AKY-1189 (actinium-225; 225 Ac) a potent alpha-emitting radioisotope in the ...
FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...
The US Food and Drug Administration (FDA) has fast-tracked a promising new gene therapy, KB707, which is inhaled as a fine mist for the targeted treatment of advanced or metastatic non-small-cell lung ...
Among the 10 patients with CCNE1-amplified high grade serous ovarian cancer treated with INX-315, 20% achieved a partial response and 80% achieved stable disease. The Food and Drug Administration (FDA ...
The average age of men who get diagnosed is 67.
Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results